Results 201 to 210 of about 21,159,025 (295)

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis. [PDF]

Hemasphere
Houot R, Lemoine J, Claudel A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Coville J, Llamas-Gutierrez F, Tarte K, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F.   +29 more
europepmc   +1 more source

Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma

Clinical Pharmacology &Therapeutics, EarlyView.
External control (EC) arms using routine data can be used as comparators in clinical trials under certain conditions. The objective of this study was to assess the ability of an EC arm to replicate outcomes of a randomized controlled trial (RCT) arm receiving the same treatment strategy in advanced stage classical Hodgkin lymphoma and serve as ...
Olivia Febvey‐Combes, Cédric Rossi, Behrouz Kassai, Tesla Murairi Mirimo, Loïc Chartier, Fanny Cherblanc, Emeline Cugnod, Hervé Ghesquières, Aurélien Belot   +8 more
wiley   +1 more source

Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature. [PDF]

Ann Hematol
Kirkgöz K, Weisel K, Bokemeyer C, von Kroge S.   +3 more
europepmc   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Diffuse Large B-cell Lymphoma With Tumor Thrombus in the Superior Mesenteric Vein: A Case Report. [PDF]

Cureus
Katahira T, Ohizumi Y, Akahane M, Yoshioka N, Hayashi Y, Kiryu S.   +5 more
europepmc   +1 more source

A practical difference from the normal approach to evaluate natural killer (NK) cells and NK cell neoplasms by flow cytometry

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Natural killer (NK) cell neoplasms span indolent to highly aggressive entities, and flow cytometric immunophenotyping is central to their detection and classification. However, distinguishing reactive from neoplastic NK cell expansions can be challenging because NK cells lack somatically recombined antigen receptors, and reactive states may ...
Aaron J. Wilk, Afshin Shameli, Erik Ames, Jonathan R. Fromm, Bartosz Grzywacz, Min Shi, Sindhu Cherian, Jean Oak   +7 more
wiley   +1 more source

Primary Prostatic Diffuse Large B-Cell Lymphoma Mimicking Prostate Cancer With a Normal Prostate-Specific Antigen Level. [PDF]

IJU Case Rep
Amamoto K, Nakamura Y, Fukushima H, Harada J, Matsuda T, Ito I, Mitsunari K, Matsuo T, Ohba K, Imamura R.   +9 more
europepmc   +1 more source

Subset‐specific and tissue‐specific expression of NK‐cell markers and killer immunoglobulin‐like receptors: Implications for NK‐cell clonality assessment

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate immunophenotypic evaluation of natural killer (NK)‐cell neoplasms is challenging because NK‐cells lack somatically rearranged antigen receptors, are comprised of phenotypically distinct subsets, and exhibit tissue‐specific subset distribution. We developed a flow cytometry (FC) panel for NK‐cell immunophenotypic analysis and clonality
Valerie Woodings, Orrin Koepke, Jason E. Love, Alireza Torabi, Lianqun Qiu, Jonathan R. Fromm, Sindhu Cherian, Afshin Shameli   +7 more
wiley   +1 more source

Harmonizing flow‐based quantification of CD19‐directed CAR‐T cells: Results from a multi‐center interlaboratory comparison

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract CD19‐directed CAR‐T cell therapy has become the standard of care for the treatment of relapsed/refractory LBCL, MCL, FL and BCP‐ALL. Expansion of CAR‐T cells in the peripheral blood (PB) of patients in the first weeks after infusion is an important biomarker for the prediction of therapy response and occurrence of toxicities.
Gerulf Hänel, Veit Bücklein, Carolina Berger, Anita Badbaran, Boris Fehse, Guranda Chitadze, Deniz Nogueira Gezer, Michael Hundemer, Wolfgang Kern, Sarah Klapproth, Ines Peschel‐Schaar, Christiane Siewert, Simon Völkl, Maria Xydia, Thomas Nebe, Michael Spannagl, Marion Subklewe   +16 more
wiley   +1 more source